Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)open access
- Authors
- Do, YR[Do, Young Rok]; Kwak, JY[Kwak, Jae-Yong]; Kim, JA[Kim, Jeong A.]; Kim, HJ[Kim, Hyeoung Joon]; Chung, JS[Chung, Joo Seop]; Shin, HJ[Shin, Ho-Jin]; Kim, SH[Kim, Sung-Hyun]; Bunworasate, U[Bunworasate, Udomsak]; Choi, CW[Choi, Chul Won]; Zang, DY[Zang, Dae Young]; Oh, SJ[Oh, Suk Joong]; Jootar, S[Jootar, Saengsuree]; Reksodiputro, AH[Reksodiputro, Ary Harryanto]; Lee, WS[Lee, Won Sik]; Mun, YC[Mun, Yeung-Chul]; Kong, JH[Kong, Jee Hyun]; Caguioa, PB[Caguioa, Priscilla B.]; Kim, H[Kim, Hawk]; Park, J[Park, Jinny]; Kim, DW[Kim, Dong-Wook]
- Issue Date
- Apr-2020
- Publisher
- WILEY
- Keywords
- chronic myeloid leukaemia; imatinib; newly diagnosed; long-term data; radotinib
- Citation
- BRITISH JOURNAL OF HAEMATOLOGY, v.189, no.2, pp.303 - 312
- Indexed
- SCIE
SCOPUS
- Journal Title
- BRITISH JOURNAL OF HAEMATOLOGY
- Volume
- 189
- Number
- 2
- Start Page
- 303
- End Page
- 312
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/7653
- DOI
- 10.1111/bjh.16381
- ISSN
- 0007-1048
- Abstract
- In the phase 3 study RERISE, patients with newly diagnosed chronic myeloid leukaemia in chronic phase demonstrated significantly faster and higher rates of major molecular response (MMR) with twice-daily radotinib 300 mg (n = 79) or 400 mg (n = 81) than with once-daily imatinib 400 mg (n = 81) after 12 months. With >= 48 months' follow-up, MMR was higher with radotinib 300 mg (86%) or 400 mg (83%) than with imatinib (75%). Among patients with BCR-ABL1 <= 10% at three months, MMR and molecular response 4 center dot 5 (MR4 center dot 5) were achieved within 48 months by more radotinib-treated patients (300 mg: 84% and 52%, respectively; 400 mg: 74% and 44%, respectively) than imatinib-treated patients (71% and 44%, respectively). Estimated overall and progression-free survival rates at 48 months were not significantly different between imatinib (94% and 94%, respectively) and radotinib 300 mg (99% and 97%, respectively) or 400 mg (95% and 93%, respectively). The treatment failure rate was significantly higher with imatinib (19%) than with radotinib 300 mg (6%; P = 0 center dot 0197) or 400 mg (5%; P = 0 center dot 0072). Safety profiles were consistent with previous reports; most adverse events occurred within 12 months. Radotinib continues to demonstrate robust, deep molecular responses, suggesting that treatment-free remission may be attainable.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/7653)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.